

A National Cancer Policy Forum Workshop in Collaboration with the Forum on Drug Discovery, Development, and Translation



Join the Conversation: #OncologyDrugDev



Overview of the Workshop

Richard L. Schilsky





Workshop Planning Committee Members

CHAIR: RICHARD L. SCHILSKY

AMY ABERNETHY

JEFF ALLEN

KENNETH ANDERSON

MARGARET ANDERSON

MONICA BERTAGNOLLI

GIDEON BLUMENTHAL

HEDVIG HRICAK

RONALD KLINE

AMY MCKEE

REBECCA PENTZ

STEVEN PIANTADOSI

MACE ROTHENBERG

DANIEL J. SARGENT

DEBORAH SCHRAG

MARC THEORET

SUZANNE L. TOPALIAN

NATIONAL CANCER POLICY FORUM STAFF

SHARYL NASS

ERIN BALOGH

CYNDI TRANG

SYLARA MARIE CRUZ

DRUG FORUM STAFF

ANNE CLAIBORNE

REBECCA ENGLISH

AMANDA WAGNER GEE

MORGAN BONAME

OLIVIA YOST



In Memoriam

Planning Committee Member Dan Sargent



August 22, 1970 – September 22, 2016

Thanks to our Sponsors



**Centers for Disease Control and Prevention
National Cancer Institute/National Institutes of Health
American Association for Cancer Research
American Cancer Society
American College of Radiology
American Society of Clinical Oncology
American Society of Hematology
American Society for Radiation Oncology
Association of American Cancer Institutes
AstraZeneca
Bristol-Myers Squibb
Cancer Support Community
CEO Roundtable on Cancer
Helsinn Group
LIVESTRONG Foundation
National Comprehensive Cancer Network
Novartis Oncology
Oncology Nursing Society
Pfizer**

**AbbVie
American Diabetes Association
American Society for Microbiology
Amgen Inc.
Association of American Medical Colleges
AstraZeneca
Baxalta
Burroughs Wellcome Fund
Critical Path Institute
Eli Lilly & Company
FasterCures
Food and Drug Administration
Friends of Cancer Research
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
National Institutes of Health
New England Journal of Medicine
Pfizer Inc.
Sanofi
Takeda**



Overarching Goals

To examine the current paradigm for cancer drug development:

- **Highlight challenges** with the traditional phased drug development process
- **Explore opportunities** to promote seamless cancer drug development and to learn throughout the life cycle of a drug

To suggest strategies to:

- **Improve the collection of information** across the cancer therapy lifecycle
 - **Streamline and adapt drug development** plans based on compelling evidence
 - **Consider ethical and regulatory implications** for seamless cancer drug development
- 

Workshop Agenda December 12

Session 1

- **Vision for a Seamless Cancer Drug Development Paradigm**

Session 2

- **Case Studies and Lessons Learned From Recent Experiences**

Session 3

- **Flexible Drug Development and Decision Making**

Session 4

- **Continuous Evidence Generation Across the Cancer Therapy Lifecycle**

Workshop Agenda December 13

Moonshot

- **The National Cancer Moonshot Initiative and Seamless Drug Development**

Session 5

- **Managing Benefit and Risk in Seamless Cancer Drug Development**

Session 6

- **Stakeholder Perspectives: Goals of the New Paradigm and Priorities for the Path Forward**

Wrap Up

- **Closing Remarks**